Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

Murugan Kalimutho, Kate Parsons, Deepak Mittal, J. Alejandro López, Sriganesh Srihari, Kum Kum Khanna

Research output: Contribution to journalReview articlepeer-review

178 Citations (Scopus)


Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast cancers that have a poor clinical outcome. Although no approved targeted therapy is available for TNBCs, molecular-profiling efforts have revealed promising molecular targets, with several candidate compounds having now entered clinical trials for TNBC patients. However, initial results remain modest, thereby highlighting challenges potentially involving intra- and intertumoral heterogeneity and acquisition of therapy resistance. We present a comprehensive review on emerging targeted therapies for treating TNBCs, including the promising approach of immunotherapy and the prognostic value of tumor-infiltrating lymphocytes. We discuss the impact of pathway rewiring in the acquisition of drug resistance, and the prospect of employing combination therapy strategies to overcome challenges towards identifying clinically-viable targeted treatment options for TNBC.

Original languageEnglish
Pages (from-to)822-846
Number of pages25
JournalTrends in Pharmacological Sciences
Issue number12
Publication statusPublished or Issued - 1 Dec 2015

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this